2,6-Diamino-6-azidohexanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2,6-Diamino-6-azidohexanoic acid
• 英文别名: 2,6-diamino-6-azidohexanoic acid
• 化学式: C6H13N5O2
• 分子量: 187.2
• InChiKey: QFLNJOIJUNDRFH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.2
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  104
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Methods of Synthesizing and Using Peg-Like Fluorochromes
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20150258217A1

  公开（公告）日：2015-09-17

  Fluorescent compounds include near infrared fluorochromes that are covalently linked to polyethylene glycol (PEG). The compounds behave like PEG in biological systems. One fluorescent compound has the formula (I): wherein R 1 is a fluorescent moiety having an absorption wavelength maxima in the range of 450 to 1500 nanometers, R 2 is a non-reactive moiety, and n is an integer. Another fluorescent compound has the formula (II): wherein R 1 is a fluorescent moiety having an absorption wavelength maxima in the range of 450 to 1500 nanometers, R 2 is a non-reactive moiety, R 3 is a scaffold including an amino acid group, and n is an integer. The scaffold can be attached to a chelate, protein, enzyme, peptide, antibody, or drug that can target a site in a subject.

  荧光化合物包括共价连接到聚乙二醇（PEG）的近红外荧光染料。这些化合物在生物系统中的行为类似于PEG。其中一种荧光化合物的化学式为（I）：其中，R1是一个荧光基团，其吸收波长最大值在450到1500纳米的范围内，R2是一个非反应性基团，n是一个整数。另一种荧光化合物的化学式为（II）：其中，R1是一个荧光基团，其吸收波长最大值在450到1500纳米的范围内，R2是一个非反应性基团，R3是一个包括氨基酸基团的支架，n是一个整数。支架可以连接到螯合剂、蛋白质、酶、肽、抗体或药物，以定位到主体中的某个位点。
• GLYCO-ENGINEERED INTERLEUKIN-4 BASED ANTAGONISTS
  申请人：Julius-Maximilians-Universität Würzburg

  公开号：EP3553078A1

  公开（公告）日：2019-10-16

  The present invention relates to IL-4 muteins capable of inhibiting IL-4 and/or IL-13 signalling, wherein a non-protein-polymer is conjugated to the mutein via a mutated amino acid, which allows site-directed conjugation of a non-protein polymer. The present invention further relates to nucleic acids and vectors encoding the IL-4 muteins as well as pharmaceutical compositions, kit of parts comprising the IL-4 muteins. The invention further relates to the IL-4 muteins for use in methods of treatment.

  本发明涉及能够抑制IL-4和/或IL-13信号传导的IL-4静音素，其中通过突变氨基酸将非蛋白聚合物与静音素连接，从而实现非蛋白聚合物的定点连接。本发明进一步涉及编码IL-4静音素的核酸和载体，以及包含IL-4静音素的药物组合物、试剂盒。本发明进一步涉及用于治疗方法的IL-4静音素。
• LONG-ACTING CONJUGATE OF GLUCAGON-LIKE PEPTIDE-2 (GLP-2) DERIVATIVE
  申请人：Hanmi Pharm. Co., Ltd.

  公开号：EP3689898A1

  公开（公告）日：2020-08-05

  The present invention relates to a glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof. Additionally, the present invention relates to a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof.

  本发明涉及一种胰高血糖素样肽-2（GLP-2）衍生物、其共轭物及其用途。此外，本发明还涉及一种制备胰高血糖素样肽-2（GLP-2）衍生物及其共轭物的方法。
• Long-acting conjugates of GLP-2 derivatives
  申请人：HANMI PHARM. CO., LTD.

  公开号：US11530249B2

  公开（公告）日：2022-12-20

  A glucagon-like peptide-2 (GLP-2) derivative, a conjugate thereof, and a use thereof are disclosed. Additionally, a method for preparing a glucagon-like peptide-2 (GLP-2) derivative and a conjugate thereof is disclosed.

  本研究公开了一种胰高血糖素样肽-2（GLP-2）衍生物、其共轭物及其用途。此外，还公开了一种制备胰高血糖素样肽-2（GLP-2）衍生物及其共轭物的方法。
• TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER
  申请人：Paul Scherrer Institut

  公开号：EP3941526A1

  公开（公告）日：2022-01-26